Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @LifeSciAdvisors
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @LifeSciAdvisors
-
Inventiva
$IVA Full-Year 2019: Cash position and revenueshttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Phio Pharmaceuticals
$PHIO Announces $1.74 Million Registered Direct Offering Priced At-the-Markethttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Acerus
$ASP.to$ASPCF Announces Acceptance of Two NATESTO® Clinical Studies for Presentation at the American Urological Association Annual Scientific Programhttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Oncocyte
$OCX Closes Merger Agreement to Acquire Insight Geneticshttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
HTG Molecular Diagnostics
$HTGM: EdgeSeq miRNA Whole Transcriptome Assay is Highly Reproducible in Biofluids for Potential Use as a Biomarkerhttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Salarius Pharmaceuticals
$SLRX to Present at the BIO CEO & Investor Conferencehttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$TYME Announces Third Quarter Fiscal 2020 Financial and Operating Resultshttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Emmaus Life Sciences
$EMMA Reports Preliminary Gross Sales for the Three Months Ended December 31, 2019https://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CytoSorbents
$CTSO: CytoSorb Used Successfully to Help Treat Grade 4 Cytokine Release Syndrome Following CAR T-cell Immunotherapy in First Published Case Reporthttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Trevena
$TRVN to Present at the 2020 BIO CEO & Investor Conferencehttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Kamada
$KMDA to Announce Fourth Quarter and Fiscal Year Ended December 31, 2019 Financial Results and Host Conference Call on February 12, 2020https://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Genkyotex
$GKTX.pa Announces Its Financial Calendar For 2020https://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Protalix BioTherapeutics
$PLX to Participate in the 2020 BIO CEO & Investor Conference and the Noble Capital Markets' 16th Annual Small & Microcap Investor Conferencehttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Outlook Therapeutics
$OTLK to Present at the 2020 BIO CEO & Investor Conferencehttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Immutep
$IMMP to Present TACTI-002 Interim Data at German Cancer Congresshttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Salarius
$SLRX Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitorshttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Altimmune
$ALT to Present at Upcoming Investor and Scientific Conferenceshttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Compugen
$CGEN Announces New U.S. Patent for Methods of Screening for Anti-PVRIG AntibodiesHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Inventiva
$IVA.nx selected to present the positive results from its Phase IIa clinical study with odiparcil in MPS VI at the 16th Annual WORLDSymposiumhttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CorMedix
$CRMD Announces FDA Grant of Rolling Review of Neutrolin® New Drug Applicationhttps://www.lifesciadvisors.com/news/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.